• Approved News

Everest Medicines：LNZ100 (1.44% aceclidine ophthalmic solution, US brand name VIZZ) — Everest Medicines has acquired the exclusive rights to develop, manufacture, and commercialize this product in Greater China, including mainland China, Hong Kong SAR, Macao SAR, and Taiwan region.

• Approved News

CSPC：SYS6063 Dual-Target CAR-T Therapy Receives Clinical Trial Approval

• Approved News

Nhwa：NHL35700 initiates its first Phase III clinical trial.

• Drug news

How much does Xiangerkang (Methyldopa Tablets) Cost& price without insurance in China?

• Approved News

Roche ：Zilebesiranhas been granted Breakthrough Therapy designation.

• Approved News

Merck & Co. ：PifeltroDoravirine Granted Priority Review

• Approved News

GeneScience ：CAMCEVI®Leuprolidehas been formally accepted for review.

• Approved News

Livzon：Lecankitug approved for marketing in China

• Approved News

Hansoh ：Olatorepatide Phase III Study Meets Primary Endpoint

• Drug news

How much does Orpathys (Savolitinib Tablets) Cost& price without insurance in China?

• Drug news

How much does GaoruiZhe (Golidocitinib Capsules) Cost& price without insurance in China?

• Drug news

How much does OPDIVO (Nivolumab Injection) Cost& price without insurance in China?